KCK-based Cingulate completed a 6.9 million-share offering for almost 58 cents a share. The company is pushing its first time-release ADHD drug through clinical trials.Cingulate raises $4M from public offering of almost 7M shares
KCK-based Cingulate completed a 6.9 million-share offering for almost 58 cents a share. The company is pushing its first time-release ADHD drug through clinical trials.